Peptoids and Methods for attenuating inflammatory response


Technology / 18-12:    Peptoids and Methods for Attenuating Inflammatory Response

Inventor:                     Shannon Servoss, Melissa Moss, Lauren Wolf

Status:                        This invention is available for licensing 


General Description


RAGE expression is low in most tissues in the young/healthy and increases in RAGE expression are associated with aging or conditions of chronic inflammation. Targeting RAGE could function as a preventative measure as well as a treatment option for a wide array of conditions (as previously mentioned.  This is a method related to the reversing and/or inhibiting of RAGE expression in a cell.  The future use of this technology is that of a method to reverse existing RAGE expression, as well as prevent RAGE expression with pre-treatment.  It can potentially become a therapeutic for more diseases/conditions, in the future.




•       Targeting RAGE could function as a preventative measure as well as a treatment option for a wide array of conditions, as previously mentioned.




Many diseases/conditions associated with aging and/or chronic inflammation— from specific diseases like Multiple Sclerosis and Alzheimer’s disease, to conditions such as depression and obesity. 




The global peptide therapeutics market is expected to reach USD 48.04 billion by 2025, according to a new report by Grand View Research, Inc. Increasing demand for efficient & rapid-acting therapeutics for treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, are anticipated to propel market growth.


For interested parties seeking further information, feel free to contact:

Mark Allen Lanoue

Technology Manager / Tech Ventures

University of Arkansas

(479) 575-7243




Patent Information:
For Information, Contact:
Mark Lanoue
Technology Manager
University of Arkansas
Shannon Servoss
Melissa Moss
Lauren Wolf
© 2020. All Rights Reserved. Powered by Inteum